By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products Administration (NMPA) has approved a Phase 1 clinical trial evaluating HLX37 in combination with chemotherapy or HLX43 for the treatment of advanced/metastatic solid tumors.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Phase 1 clinical trial authorization |
| Lead Compound | HLX37 – recombinant humanized anti-PD-L1/anti-VEGF bispecific antibody |
| Combination Partners | Standard chemotherapy regimens and HLX43 (PD-L1-targeting ADC) |
| Indication | Advanced/metastatic solid tumors |
| Developer | Henlius (wholly-owned subsidiary of Fosun Pharma) |
| Approval Date | 14 Jul 2026 |
Drug Profiles & Mechanisms of Action
HLX37 – Dual-Targeting Bispecific Antibody
- Molecule Type: Recombinant humanized IgG bispecific antibody
- Targets: PD-L1 (immune checkpoint) and VEGF (angiogenesis factor)
- Mechanism: Simultaneously blocks tumor immune evasion and angiogenesis pathways
- Development Status: Phase 1 initiation approved
- Intellectual Property: Independently developed by Henlius with full IP rights
HLX43 – Next-Generation Antibody-Drug Conjugate
- Molecule Type: PD-L1-targeting antibody-drug conjugate (ADC)
- Antibody Component: Independently developed PD-L1-targeting antibody (Henlius)
- Payload: Novel DNA topoisomerase I inhibitor small-molecule toxin
- Linker Technology: Proprietary peptide linker (licensed technology)
- Mechanism: Targeted delivery of cytotoxic payload to PD-L1-expressing tumor cells
- Indication: Advanced/metastatic solid tumors
Clinical Development Strategy
| Trial Arm | Combination | Rationale |
|---|---|---|
| Arm A | HLX37 + Chemotherapy | Dual pathway inhibition enhances chemo sensitivity |
| Arm B | HLX37 + HLX43 | Triple mechanism: immune activation + angiogenesis inhibition + targeted cytotoxicity |
| Primary Endpoints | Safety, tolerability, maximum tolerated dose (MTD) | Establish foundation for Phase 2 expansion |
| Secondary Endpoints | Preliminary efficacy, pharmacokinetics, biomarker analysis | Identify optimal patient populations |
The combination approach represents a sophisticated strategy to overcome resistance mechanisms commonly observed with single-agent immunotherapies and targeted therapies in advanced solid tumors.
Market Impact & Strategic Implications
- Competitive Landscape: The bispecific + ADC combination positions Fosun/Henlius at the forefront of next-generation immuno-oncology combinations, competing with global leaders like Roche, Merck, and AstraZeneca
- Addressable Market: Advanced/metastatic solid tumors represent a $75+ billion global market opportunity, with combination therapies commanding premium pricing
- Pipeline Synergy: Leverages Henlius’ established capabilities in both bispecific antibodies and ADC development, creating operational efficiencies
- Global Potential: Successful clinical data could support international regulatory filings, particularly in markets with high solid tumor burden
- Strategic Positioning: Demonstrates Fosun Pharma’s commitment to innovative oncology therapeutics beyond biosimilars, supporting premium valuation multiples
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory approvals, and market opportunities for HLX37 and HLX43. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech